Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
specificAn oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).
15
Centers
15
Active Trials
—
Cancer Funding
Top Centers for Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted(15)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 53.3 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 53.3 |
| 3 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive Active Research Program | 53.3 |
| 4 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 53.3 |
| 5 | NCI Comprehensive Active Research Program | 53.3 |
| 6 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 53.3 |
| 7 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 53.3 |
| 8 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 53.3 |
| 9 | NCI Clinical Active Research Program | 53.3 |
| 10 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 53.3 |
| 11 | Medical College of Wisconsin Cancer CenterMilwaukee, WI Active Research Program | 53.3 |
| 12 | Cleveland Clinic Cancer CenterCleveland, OH Active Research Program | 53.3 |
| 13 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program | 53.3 |
| 14 | Rutgers Cancer InstituteNew Brunswick, NJ NCI Comprehensive Active Research Program | 53.3 |
| 15 | Boston University Cancer CenterBoston, MA Active Research Program | 53.3 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →